Skip to main content
. Author manuscript; available in PMC: 2020 Oct 28.
Published in final edited form as: Clin Genitourin Cancer. 2016 Sep 8;15(2):326–335.e3. doi: 10.1016/j.clgc.2016.08.020

Figure 1.

Figure 1

Kaplan-Meier curves of FFBF for all patients (top left), FFDM (top right), CSS (lower left), and OS (lower right). The x-axis on each plot is follow-up time (in months); the y-axis is percent. The number at risk of patients on MHSs (red lines) and those not on MHSs (blue lines) are listed for reference in each plot. MHS use was associated with improved OS in this analysis; but not with a change in FFBF, DM, or CSS.